SMAD7 and prostate cancer: We have recently reported that both TβRI and c-Jun are expressed at high levels in aggressive prostate cancer tissues (Gudey et al., 2017), and high levels of Smad7 have been reported to be expressed in prostate cancer bone metastases (Nordstrand et al., 2018), providing support for the notion that active TGF-β signaling promotes prostate cancer progression and metastases, in line with our observations in this report.